A private single family office deploying proprietary family capital into Greater China's most compelling healthcare and life sciences opportunities — informed by on-the-ground presence, local market knowledge, and a disciplined approach to long-term value creation. Family-only mandate; not a public-facing investment manager.
Rubix Group (HK) Limited is a Hong Kong incorporated private single family office established in 2020 to manage the assets and investments of its controlling family and family-owned investment holding vehicles. Rubix Group serves only members of that family group; it does not offer services to the public and does not solicit, accept, or manage capital, mandates, or investment instructions from persons outside the family group.
We deploy proprietary family capital into carefully selected healthcare and life sciences opportunities across Greater China — with a preference for situations where on-the-ground presence, local relationships, and deep sector understanding provide a meaningful informational advantage. We invest as principals across the healthcare value chain: biotech and therapeutics, medical devices, CRO/CDMO services, digital health, and healthcare services — with concentration, patience, and a long-term orientation.
Headquartered in Hong Kong, Rubix Group benefits from direct proximity to Greater China's healthcare capital markets, regulatory environment, and biotech ecosystem. Rubix Group shares common premises and administrative infrastructure with Rubix Capital SPC, a separate Cayman Islands legal entity, while maintaining a fully independent investment process, separate decision-making, and distinct governance. Rubix Capital SPC is a separate legal entity; any regulatory licensing held by affiliated entities applies only to those entities and does not extend to Rubix Group (HK) Limited.
Regulatory status. Rubix Group (HK) Limited is not licensed by the Securities and Futures Commission of Hong Kong to carry on any regulated activity, including Type 1 (dealing in securities), Type 4 (advising on securities), or Type 9 (asset management). Any reference on this website to a "single family office" or to Hong Kong's family office tax concession relates to tax treatment only and does not imply SFC authorisation, licensing, or regulated status.
We believe that the most compelling risk-adjusted healthcare opportunities in Greater China are best identified and evaluated from within the region — through relationships built over time, an understanding of local regulatory dynamics, and a rigorous approach to the management of the family's own capital.
Our Hong Kong base provides direct access to Greater China's healthcare deal flow, regulatory landscape, and biotech networks. We believe proximity to the companies and healthcare ecosystems in which we invest is a prerequisite for informed decision-making — not an optional enhancement.
We favour a concentrated approach — a limited number of high-conviction positions where our research and local knowledge provide a differentiated perspective. We are willing to accept periods of illiquidity and shorter-term volatility in exchange for what we believe to be superior long-term compounding.
As a genuine single family office, Rubix Group maintains a fully independent investment process and autonomous decision-making authority. While sharing common premises and administrative infrastructure with Rubix Capital, all investment research, due diligence, and portfolio decisions are conducted independently.
We allocate capital across healthcare and life sciences sub-sectors where Greater China's structural advantages — regulatory reform, scientific maturation, ageing demographics, and domestic demand — create durable growth trajectories that we can evaluate from our position on the ground.
Greater China's biotech ecosystem has matured rapidly — producing globally competitive therapeutics, novel biologics, and innovative drug candidates. We invest across the development lifecycle where local regulatory knowledge and management access provide an informational edge, from clinical-stage companies through to commercialisation.
China's medical device sector is undergoing a generational shift — driven by import substitution policies, domestic innovation, and rising healthcare expenditure. We focus on companies developing differentiated technologies with domestic market relevance and, increasingly, global commercial potential.
An ageing population and expanding insurance coverage are reshaping Greater China's healthcare services landscape. We invest selectively in platforms and providers positioned to benefit from structural demand growth — CRO/CDMO services, hospital groups, specialty clinics, and the infrastructure supporting modern healthcare delivery.
We monitor and selectively invest in the convergence of technology and healthcare across Greater China — from AI-driven drug discovery and computational biology through telemedicine platforms, real-world evidence analytics, and the digital infrastructure enabling precision medicine at scale.
Proprietary healthcare deal flow sourced through local biotech networks, venture capital relationships across Greater China, life sciences conferences, and the family office's own professional relationships developed through sustained on-the-ground presence in Hong Kong.
Independently conducted commercial, scientific, and operational due diligence — leveraging local language capability, direct management access, clinical and regulatory assessment, on-site visits, competitive landscape analysis, and healthcare reference networks that are difficult to replicate from outside the region.
Bespoke investment structures for the family's own capital — direct equity, convertible instruments, structured notes, and special purpose vehicles tailored to each healthcare opportunity's regulatory, clinical, and commercial requirements within Greater China.
Active engagement by the family with its principal investee companies through board representation, strategic advisory, clinical milestone monitoring, and ongoing operational oversight — facilitated by geographic proximity and established relationships within Greater China's healthcare ecosystem.
Robust internal governance with independent risk monitoring, concentration limits, and multi-jurisdictional regulatory compliance. Administrative compliance support provided through shared infrastructure with appropriate information barriers.
Considered exit planning — IPO positioning on HKEX, Shanghai, or Shenzhen exchanges for healthcare companies, trade sale facilitation to strategic pharmaceutical and medtech acquirers, secondary market access, and structured liquidity solutions optimised across relevant jurisdictions.
Local biotech networks, healthcare industry relationships, Greater China life sciences conferences, management referrals, and proprietary deal sourcing through on-the-ground presence in Hong Kong's healthcare ecosystem.
Scientific and commercial positioning analysis, competitive landscape, management team assessment, regulatory pathway evaluation, and preliminary clinical and commercial viability assessment.
On-site operational review, clinical data assessment, local reference checks, financial modelling, regulatory and IP due diligence, and independent verification through regional healthcare expert networks.
Term negotiation, structure optimisation, legal documentation, governance provisions, and milestone frameworks — structured for the relevant Greater China regulatory context.
Active board engagement, strategic advisory, ongoing operational monitoring, exit planning, and value realisation — supported by continued local market presence.
Our on-the-ground presence in Hong Kong provides direct access to each of Greater China's key healthcare markets and biotech innovation centres.
Rubix Group operates within a carefully designed multi-entity structure — providing regulatory compliance, operational efficiency, and appropriate structuring for Greater China healthcare investment activities.
Formal IC governance with documented decision protocols, quorum requirements, and escalation procedures for all principal investments exceeding defined thresholds.
Access to healthcare sector specialists, clinical advisors, local market experts, and experienced life sciences practitioners providing independent validation of investment theses and ongoing portfolio company monitoring across Greater China.
Independent position-level risk monitoring with concentration limits, currency and regulatory exposure analysis, and scenario stress testing conducted through Rubix Group's own risk management processes.
Multi-jurisdictional compliance oversight spanning Hong Kong, BVI, Cayman, and applicable PRC regulatory frameworks. Ongoing monitoring of healthcare regulatory developments and policy changes relevant to Greater China healthcare investment activities.
Formal policies governing conflicts between Rubix Group principal investments and Rubix Capital multi-family office activities — information barriers and allocation protocols.
Independent audit, IFRS-compliant financial reporting, and comprehensive family reporting. Transparent governance documentation and record-keeping.
Rubix Group is led by a single executive responsible for the family's healthcare and life sciences principal investing programme — combining decades of cross-jurisdictional capital allocation experience with on-the-ground proximity to Greater China.
Alexander Ariana serves as Chief Executive Officer of Rubix Group (HK) Limited, with responsibility for the family's principal investing programme across Greater China healthcare and life sciences. He oversees deal origination, due diligence, transaction structuring, and stewardship of family principal positions across biotech and therapeutics, medical devices, healthcare services, and digital health.
His background spans cross-jurisdictional capital allocation, fund-of-funds and direct transaction underwriting, and multi-jurisdictional fund and family-office structuring across Hong Kong, the British Virgin Islands, the Cayman Islands, and additional centres. He brings a disciplined endowment-model framework to the family's principal investments and maintains active engagement with healthcare management teams, clinical advisors, and life sciences operators across the region.
"We believe the most informed healthcare investment decisions are made closest to where science becomes medicine. In Greater China, that means being present — understanding the regulatory landscape from within, building relationships across the biotech ecosystem, and having the patience to invest with genuine conviction."
As a private single family office, Rubix Group does not accept external capital or investment mandates. We welcome introductions from healthcare entrepreneurs, biotech management teams, clinical advisors, and life sciences professionals operating within Greater China seeking principal capital from a long-term family investor.